[1]
|
中华医学会妇产科学分会内分泌学组. 女性高催乳素血症诊治共识[J]. 中华妇产科杂志, 2016, 51(3): 161-168.
|
[2]
|
Inder, W.J. and Jang, C. (2022) Treatment of Prolactinoma. Medicina, 58, Article 1095.
https://doi.org/10.3390/medicina58081095
|
[3]
|
Woodmansee, W.W. (2019) Pituitary Disorders in Pregnancy. Neurologic Clinics, 37, 63-83.
https://doi.org/10.1016/j.ncl.2018.09.009
|
[4]
|
李娟, 郑巧玲, 周琼, 黄桦, 王晶晶, 张峻. BRC治疗妊娠垂体泌乳素瘤患者的安全性研究进展[J]. 实用药物与临床, 2015(12): 1505-1508.
|
[5]
|
Araujo, B., Belo, S. and Carvalho, D. (2017) Pregnancy and Tumor Outcomes in Women with Prolactinoma. Experimental and Clinical Endocrinology & Diabetes, 125, 642-648. https://doi.org/10.1055/s-0043-112861
|
[6]
|
苏菊, 陈韵仙, 石萍, 张素珍, 李文敏. BRC治疗泌乳——闭经综合征后妊娠的观察(附25例分析) [J]. 天津医药, 1986(9): 519-522.
|
[7]
|
Ikegami, H., Aono, T., Koizumi, K., Koike, K., Fukui, H. and Tanizawa, O. (1987) Relationship between the Methods of Treatment for Prolactino-Mas and the Puerperal Lactation. Fertility and Sterility, 47, 867-869.
|
[8]
|
汤绍芳, 刘铭. 泌乳素瘤患者的围妊娠期管理[J]. 国际内分泌代谢杂志, 2021, 41(6): 569-572.
https://doi.org/10.3760/cma.j.cn121383-20211006-10007
|
[9]
|
Beshyah, S.A., Sherif, I.H., Chentli, F., et al. (2016) Management of Prolactinomas: A Survey of Physicians from the Middle East and North Africa. Pituitary, 20, 231-240. https://doi.org/10.1007/s11102-016-0767-5
|
[10]
|
Luger, A., Broersen, L.H.A., Biermasz, N.R., Biller, B.M.K., Buchfelder, M., Chanson, P., Jorgensen, J.O.L., Kelestimur, F., Llahana, S., Maiter, D., Mintzio, G., Petraglia, F., Verkauskiene, R., Webb, S.M. and Dekkers, O.M. (2021) ESE Clinical Practice Guideline on Functioning and Nonfunctioning Pituitary Adenomas in Pregnancy. European Journal of Endocrinology, 185, G1-G33. https://doi.org/10.1530/EJE-21-0462
|
[11]
|
Cozzi, R., Ambrosio, M.R., Attanasio, R., Battista, C., Bozzao, A., Caputo, M., Ciccarelli, E., De Marinis, L., De Menis, E., Faustini Fustini, M., Grimaldi, F., Lania, A., Lasio, G., Logoluso, F., Losa, M., Maffei, P., Milani, D., Poggi, M., Zini, M., Katznelson, L., Luger, A. and Poiana, C. (2022) Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position Statement for Clinical Practice: Prolactin-Secreting Tumors. European Journal of Endocrinology, 186, P1-P33. https://doi.org/10.1530/EJE-21-0977
|
[12]
|
Petersenn, S., Christ-Crain, M., Droste, M., Finke, R., Flitsch, J., Kreitschmann-Andermahr, I., Luger, A., Schopohl, J. and Stalla, G. (2019) Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment? Geburtshilfe und Frauenheilkunde, 79, 365-374. https://doi.org/10.1055/a-0794-7587
|
[13]
|
Vasco Ramirez, M. and Valencia, G. (2020) Anesthesia for Nonobstetric Surgery in Pregnancy. Clinical Obstetrics and Gynecology, 63, 351-363. https://doi.org/10.1097/GRF.0000000000000532
|
[14]
|
中国垂体腺瘤协作组. 中国垂体催乳素腺瘤诊治共识: 2014版[J]. 中华医学杂志, 2014, 94(31): 2406-2411.
|
[15]
|
Gillam, M.P., Molitch, M.E., Lombardi, G. and Colao, A. (2006) Advances in the Treatment of Prolactinomas. Endocrine Reviews, 27, 485-534. https://doi.org/10.1210/er.2005-9998
|
[16]
|
邓洁, 罗剑波, 彭聪, 等. BRC对高泌乳素血症所致不孕不育女性患者性激素水平及妊娠率的影响[J]. 中国妇幼保健, 2017, 32(14): 3260-3262.
|
[17]
|
李文媛, 韩玉芬, 王志勇, 等. 低剂量溴隐亭在难治性多囊卵巢综合征不育患者治疗中的助孕疗效观察[J]. 河南医学研究, 2015(9): 22-24. https://doi.org/10.3969/j.issn.1004-437X.2015.09.008
|
[18]
|
Auriemma, R.S., Perone, Y., Di Sarno, A., Grasso, L.F., Guerra, E., Gasperi, M., Pivonello, R. and Colao, A. (2013) Results of a Single-Center Observational 10-Year Survey Study on Recurrence of Hyperprolactinemia after Pregnancy and Lactation. The Journal of Clinical Endocrinology & Metabolism, 98, 372-379.
https://doi.org/10.1210/jc.2012-3039
|
[19]
|
Turkalj, I., Braun, P. and Krupp, P. (1982) Surveillance of Bromocriptine in Pregnancy. The Journal of the American Medical Association, 247, 1589-1591. https://doi.org/10.1001/jama.1982.03320360039028
|
[20]
|
茹意凤, 朱付凡, 黄健. 高泌乳素血症患者孕早期溴隐亭治疗对妊娠结局的影响[J]. 临床医学工程, 2015, 22(5): 576-577. https://doi.org/10.3969/j.issn.1674-4659.2015.05.0576
|
[21]
|
黄珂珂, 徐凤娟, 吴瑜玲. 溴隐亭应用于妊娠合并高泌乳素血症患者对其妊娠结局的影响[J]. 新疆医科大学学报, 2018, 41(9): 1083-1086. https://doi.org/10.3969/j.issn.1009-5551.2018.09.007
|
[22]
|
林飞阳, 吴成坤, 陈兵, 等. 溴隐亭对斑马鱼胚胎早期发育的影响[J]. 国际神经病学神经外科学杂志, 2022, 49(3): 8-13. https://doi.org/10.16636/j.cnki.jinn.1673-2642.2022.03.002
|
[23]
|
马爱团, 钟秀会, 孟立根, 等. 溴隐亭对小鼠生育的影响及其作用机理[J]. 动物学报, 2006, 52(3): 536-541.
https://doi.org/10.3969/j.issn.1674-5507.2006.03.015
|
[24]
|
Hurault-delarue, C., Montastruc, J.L., Beau, A.B., Lacroix, I. and Damase-Michel, C. (2014) Pregnancy Outcome in Women Exposed to Dopamine Agonists during Pregnancy: A Pharmacoepidemiology Study in EFEMERIS Database. Archives of Gynecology and Obstetrics, 290, 263-270. https://doi.org/10.1007/s00404-014-3210-z
|
[25]
|
Zheng, Q., Zhou, Q., Li, J., Tian, Y., Huang, H., Yao, Q., Wang, J. and Zhang, J. (2017) Placental Transfer of Bromocriptine in an ex vivo Human Placental Perfusion Model. The Journal of Maternal-Fetal & Neonatal Medicine, 32, 1155-1159. https://doi.org/10.1080/14767058.2017.1402000
|
[26]
|
Weil, C. (1986) The Safety of Bromocriptine in Long-Term Use: A Review of the Literature. Current Medical Research and Opinion, 10, 25-51. https://doi.org/10.1185/03007998609111089
|
[27]
|
钱丽波, 王珏. 妊娠合并高泌乳素血症患者孕期BRC治疗对妊娠结局的影响[J]. 世界最新医学信息文摘(连续型电子期刊), 2016, 16(4): 103-104.
|
[28]
|
Saraiva, J., Gomes, L., Paiva, S., et al. (2013) Giant Macroprolactinoma and Pregnancy. Arquivos brasileiros de endocrinologia e metabologia, 57, 558-561. https://doi.org/10.1590/S0004-27302013000700010
|
[29]
|
Raymond, J.P., Goldstein, E., Konopka, P., Leleu, M.F., Merceron, R.E. and Loria, Y. (1985) Follow-up of Children Born of Bromocriptine-Treated Mothers. Hormone Research in Paediatrics, 22, 239-246.
https://doi.org/10.1159/000180100
|
[30]
|
沙英琦. 妊娠期服用溴隐亭对其子代的影响[J]. 中国妇幼保健, 1989(1): 21.
|
[31]
|
Thorner, M.O., Besser, G.M., Jones, A., Dacie, J. and Jones, A.E. (1975) Bromocriptine Treatment of Female Infertility: Report of 13 Pregnancies. British Medical Journal, 4, 694-697. https://doi.org/10.1136/bmj.4.5998.694
|
[32]
|
Marcellin, L. and Chantry, A.A. (2015) Allaitement maternel (partie II): Méthodes d’inhibition de la lactation— Recommandations pour la pratique clinique [Breast-Feeding (Part II): Lactation Inhibition—Guidelines for Clinical Practice]. Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 44, 1080-1083.
https://doi.org/10.1016/j.jgyn.2015.09.028
|
[33]
|
Kemperman, C.J. and Zwanikken, G.J. (1987) Psychiatric Side Effects of Bromocriptine Therapy for Postpartum Galactorrhoea. Journal of the Royal Society of Medicine, 80, 387-388. https://doi.org/10.1177/014107688708000620
|
[34]
|
Peters, F., Geisthovel, F. and Breckwoldt, M. (1985) Serum Prolactin Levels in Women with Excessive Milk Production. Normalization by Transitory Prolactin Inhibition. Acta Endocrinologica, 109, 463-466.
https://doi.org/10.1530/acta.0.1090463
|
[35]
|
Cheng, W., Zhang, Z., Fu, Z.H., Ke, C. and Zhi, Z. (1996) [Management of Pituitary Adenoma in Pregnancy]. Chinese Journal of Obstetrics and Gynecology, 31, 537-539.
|